NASDAQ: ORGSOrgenesis Inc Stock
$0.50-0.02 (-3.85%)
Updated Apr 24, 2024
ORGS Price
$0.50
Fair Value Price
N/A
Market Cap
$17.24M
52 Week Low
$0.25
52 Week High
$1.50
P/E
0.26x
P/B
-0.82x
P/S
27.4x
PEG
0.19x
Dividend Yield
N/A
Revenue
$530.00k
Earnings
-$55.36M
Gross Margin
-3,084.5%
Operating Margin
-9,884.72%
Profit Margin
-10,445.5%
Debt to Equity
-1.69
Operating Cash Flow
-$15M
Beta
0.82
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ORGS Overview
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ORGS ($0.50) is trading below its intrinsic value of $11.42, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ORGS is good value based on its earnings relative to its share price (0.26x), compared to the US market average (41.27x)
P/E vs Market Valuation
ORGS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ORGS due diligence checks available for Premium users.
Be the first to know about important ORGS news, forecast changes, insider trades & much more!
ORGS News
Valuation
ORGS fair value
Fair Value of ORGS stock based on Discounted Cash Flow (DCF)
Price
$0.50
Fair Value
-$0.00
Undervalued by
594,502.61%
ORGS ($0.50) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ORGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.26x
Industry
15.69x
Market
41.27x
ORGS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ORGS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ORGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.82x
Industry
5.86x
ORGS price to earnings growth (PEG)
For valuing profitable companies with growth potential
ORGS is good value based... subscribe to Premium to read more.
PEG Value Valuation
ORGS's financial health
Profit margin
Revenue
$165.0k
Net Income
-$6.6M
Profit Margin
-4,013.9%
ORGS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ORGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$14.6M
Liabilities
$35.5M
Debt to equity
-1.69
ORGS's short-term liabilities ($16.41M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORGS's long-term liabilities ($19.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORGS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ORGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$502.0k
Investing
-$62.0k
Financing
$1.2M
ORGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ORGS vs Biotech Stocks
Orgenesis Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.